Synergistic interaction of HOXB13 and CIP2A predisposes to aggressive prostate cancer

C. Sipeky, Ping Gao, Qin Zhang, Liang Wang, Otto Ettala, Kirsi M. Talala, Teuvo L.J. Tammela, Anssi Auvinen, Fredrik Wiklund, Gong Hong Wei, Johanna Schleutker

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Distinguishing aggressive prostate cancer from indolent disease improves personalized treatment. Although only few genetic variants are known to predispose to aggressive prostate cancer, synergistic interactions of HOXB13 G84E high-risk prostate cancer susceptibility mutation with other genetic loci remain unknown. The purpose of this study was to examine the interplay of HOXB13 rs138213197 (G84E) and CIP2A rs2278911 (R229Q) germline variants on prostate cancer risk. Experimental Design: Genotyping was done in Finnish discovery cohort (n ¼ 2,738) and validated in Swedish (n ¼ 3,132) and independent Finnish (n ¼ 1,155) prostate cancer cohorts. Expression pattern analysis was followed by functional studies in prostate cancer cell models. Results: Interplay of HOXB13 (G84E) and CIP2A (R229Q) variants results in highest observed inherited prostate cancer risk (OR, 21.1; P ¼ 0.000024). In addition, this synergism indicates a significant association of HOXB13 T and CIP2A T dual carriers with elevated risk for high Gleason score (OR, 2.3; P ¼ 0.025) and worse prostate cancer–specific life expectancy (HR, 3.9; P ¼ 0.048), and it is linked with high PSA at diagnosis (OR, 3.30; P ¼ 0.028). Furthermore, combined high expression of HOXB13-CIP2A correlates with earlier biochemical recurrence. Finally, functional experiments showed that ectopic expression of variants stimulates prostate cancer cell growth and migration. In addition, we observed strong chromatin binding of HOXB13 at CIP2A locus and revealed that HOXB13 functionally promotes CIP2A transcription. The study is limited to retrospective Nordic cohorts. Conclusions: Simultaneous presence of HOXB13 T and CIP2A T alleles confers for high prostate cancer risk and aggressiveness of disease, earlier biochemical relapse, and lower disease-specific life expectancy. HOXB13 protein binds to CIP2A gene and functionally promotes CIP2A transcription.

Original languageEnglish
Pages (from-to)6265-6276
Number of pages12
JournalClinical Cancer Research
Volume24
Issue number24
DOIs
Publication statusPublished - Dec 15 2018

Fingerprint

Prostatic Neoplasms
Life Expectancy
Recurrence
Genetic Loci
Neoplasm Grading
Chromatin
Cell Movement
Prostate
Research Design
Alleles
Mutation
Growth
Genes
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Synergistic interaction of HOXB13 and CIP2A predisposes to aggressive prostate cancer. / Sipeky, C.; Gao, Ping; Zhang, Qin; Wang, Liang; Ettala, Otto; Talala, Kirsi M.; Tammela, Teuvo L.J.; Auvinen, Anssi; Wiklund, Fredrik; Wei, Gong Hong; Schleutker, Johanna.

In: Clinical Cancer Research, Vol. 24, No. 24, 15.12.2018, p. 6265-6276.

Research output: Contribution to journalArticle

Sipeky, C, Gao, P, Zhang, Q, Wang, L, Ettala, O, Talala, KM, Tammela, TLJ, Auvinen, A, Wiklund, F, Wei, GH & Schleutker, J 2018, 'Synergistic interaction of HOXB13 and CIP2A predisposes to aggressive prostate cancer', Clinical Cancer Research, vol. 24, no. 24, pp. 6265-6276. https://doi.org/10.1158/1078-0432.CCR-18-0444
Sipeky, C. ; Gao, Ping ; Zhang, Qin ; Wang, Liang ; Ettala, Otto ; Talala, Kirsi M. ; Tammela, Teuvo L.J. ; Auvinen, Anssi ; Wiklund, Fredrik ; Wei, Gong Hong ; Schleutker, Johanna. / Synergistic interaction of HOXB13 and CIP2A predisposes to aggressive prostate cancer. In: Clinical Cancer Research. 2018 ; Vol. 24, No. 24. pp. 6265-6276.
@article{813c68abb68c4efe988234443b078c43,
title = "Synergistic interaction of HOXB13 and CIP2A predisposes to aggressive prostate cancer",
abstract = "Purpose: Distinguishing aggressive prostate cancer from indolent disease improves personalized treatment. Although only few genetic variants are known to predispose to aggressive prostate cancer, synergistic interactions of HOXB13 G84E high-risk prostate cancer susceptibility mutation with other genetic loci remain unknown. The purpose of this study was to examine the interplay of HOXB13 rs138213197 (G84E) and CIP2A rs2278911 (R229Q) germline variants on prostate cancer risk. Experimental Design: Genotyping was done in Finnish discovery cohort (n ¼ 2,738) and validated in Swedish (n ¼ 3,132) and independent Finnish (n ¼ 1,155) prostate cancer cohorts. Expression pattern analysis was followed by functional studies in prostate cancer cell models. Results: Interplay of HOXB13 (G84E) and CIP2A (R229Q) variants results in highest observed inherited prostate cancer risk (OR, 21.1; P ¼ 0.000024). In addition, this synergism indicates a significant association of HOXB13 T and CIP2A T dual carriers with elevated risk for high Gleason score (OR, 2.3; P ¼ 0.025) and worse prostate cancer–specific life expectancy (HR, 3.9; P ¼ 0.048), and it is linked with high PSA at diagnosis (OR, 3.30; P ¼ 0.028). Furthermore, combined high expression of HOXB13-CIP2A correlates with earlier biochemical recurrence. Finally, functional experiments showed that ectopic expression of variants stimulates prostate cancer cell growth and migration. In addition, we observed strong chromatin binding of HOXB13 at CIP2A locus and revealed that HOXB13 functionally promotes CIP2A transcription. The study is limited to retrospective Nordic cohorts. Conclusions: Simultaneous presence of HOXB13 T and CIP2A T alleles confers for high prostate cancer risk and aggressiveness of disease, earlier biochemical relapse, and lower disease-specific life expectancy. HOXB13 protein binds to CIP2A gene and functionally promotes CIP2A transcription.",
author = "C. Sipeky and Ping Gao and Qin Zhang and Liang Wang and Otto Ettala and Talala, {Kirsi M.} and Tammela, {Teuvo L.J.} and Anssi Auvinen and Fredrik Wiklund and Wei, {Gong Hong} and Johanna Schleutker",
year = "2018",
month = "12",
day = "15",
doi = "10.1158/1078-0432.CCR-18-0444",
language = "English",
volume = "24",
pages = "6265--6276",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Synergistic interaction of HOXB13 and CIP2A predisposes to aggressive prostate cancer

AU - Sipeky, C.

AU - Gao, Ping

AU - Zhang, Qin

AU - Wang, Liang

AU - Ettala, Otto

AU - Talala, Kirsi M.

AU - Tammela, Teuvo L.J.

AU - Auvinen, Anssi

AU - Wiklund, Fredrik

AU - Wei, Gong Hong

AU - Schleutker, Johanna

PY - 2018/12/15

Y1 - 2018/12/15

N2 - Purpose: Distinguishing aggressive prostate cancer from indolent disease improves personalized treatment. Although only few genetic variants are known to predispose to aggressive prostate cancer, synergistic interactions of HOXB13 G84E high-risk prostate cancer susceptibility mutation with other genetic loci remain unknown. The purpose of this study was to examine the interplay of HOXB13 rs138213197 (G84E) and CIP2A rs2278911 (R229Q) germline variants on prostate cancer risk. Experimental Design: Genotyping was done in Finnish discovery cohort (n ¼ 2,738) and validated in Swedish (n ¼ 3,132) and independent Finnish (n ¼ 1,155) prostate cancer cohorts. Expression pattern analysis was followed by functional studies in prostate cancer cell models. Results: Interplay of HOXB13 (G84E) and CIP2A (R229Q) variants results in highest observed inherited prostate cancer risk (OR, 21.1; P ¼ 0.000024). In addition, this synergism indicates a significant association of HOXB13 T and CIP2A T dual carriers with elevated risk for high Gleason score (OR, 2.3; P ¼ 0.025) and worse prostate cancer–specific life expectancy (HR, 3.9; P ¼ 0.048), and it is linked with high PSA at diagnosis (OR, 3.30; P ¼ 0.028). Furthermore, combined high expression of HOXB13-CIP2A correlates with earlier biochemical recurrence. Finally, functional experiments showed that ectopic expression of variants stimulates prostate cancer cell growth and migration. In addition, we observed strong chromatin binding of HOXB13 at CIP2A locus and revealed that HOXB13 functionally promotes CIP2A transcription. The study is limited to retrospective Nordic cohorts. Conclusions: Simultaneous presence of HOXB13 T and CIP2A T alleles confers for high prostate cancer risk and aggressiveness of disease, earlier biochemical relapse, and lower disease-specific life expectancy. HOXB13 protein binds to CIP2A gene and functionally promotes CIP2A transcription.

AB - Purpose: Distinguishing aggressive prostate cancer from indolent disease improves personalized treatment. Although only few genetic variants are known to predispose to aggressive prostate cancer, synergistic interactions of HOXB13 G84E high-risk prostate cancer susceptibility mutation with other genetic loci remain unknown. The purpose of this study was to examine the interplay of HOXB13 rs138213197 (G84E) and CIP2A rs2278911 (R229Q) germline variants on prostate cancer risk. Experimental Design: Genotyping was done in Finnish discovery cohort (n ¼ 2,738) and validated in Swedish (n ¼ 3,132) and independent Finnish (n ¼ 1,155) prostate cancer cohorts. Expression pattern analysis was followed by functional studies in prostate cancer cell models. Results: Interplay of HOXB13 (G84E) and CIP2A (R229Q) variants results in highest observed inherited prostate cancer risk (OR, 21.1; P ¼ 0.000024). In addition, this synergism indicates a significant association of HOXB13 T and CIP2A T dual carriers with elevated risk for high Gleason score (OR, 2.3; P ¼ 0.025) and worse prostate cancer–specific life expectancy (HR, 3.9; P ¼ 0.048), and it is linked with high PSA at diagnosis (OR, 3.30; P ¼ 0.028). Furthermore, combined high expression of HOXB13-CIP2A correlates with earlier biochemical recurrence. Finally, functional experiments showed that ectopic expression of variants stimulates prostate cancer cell growth and migration. In addition, we observed strong chromatin binding of HOXB13 at CIP2A locus and revealed that HOXB13 functionally promotes CIP2A transcription. The study is limited to retrospective Nordic cohorts. Conclusions: Simultaneous presence of HOXB13 T and CIP2A T alleles confers for high prostate cancer risk and aggressiveness of disease, earlier biochemical relapse, and lower disease-specific life expectancy. HOXB13 protein binds to CIP2A gene and functionally promotes CIP2A transcription.

UR - http://www.scopus.com/inward/record.url?scp=85058213983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058213983&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-0444

DO - 10.1158/1078-0432.CCR-18-0444

M3 - Article

VL - 24

SP - 6265

EP - 6276

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 24

ER -